Implementation studies of ranibizumab for neovascular age-related macular degeneration

Keyphrases

• Neovascular Age-related Macular Degeneration (nAMD) 100%
• Ranibizumab 100%
• Neovascular AMD 100%
• Fibrous Tissue 38%
• Subfoveal 38%
• Denmark 15%
• Dosing Regimen 15%
• Atrophy 15%
• Visual Acuity 15%
• Natural Course 15%
• Pathological Changes 15%
• VEGF Inhibitors 15%
• Hazard Ratio 7%
• Treatment Regimen 7%
• Disease Course 7%
• Inflammatory Response 7%
• Clinical Characteristics 7%
• Disease Activity 7%
• Incidence Rate 7%
• Randomized Clinical Trial 7%
• Europe 7%
• First Year 7%
• Visual Outcome 7%
• Retinal pigment Epithelium 7%
• Age-related Changes 7%
• Fibrosis 7%
• Growth Pattern 7%
• Oxidative Stress 7%
• Blind People 7%
• Annual Incidence 7%
• Treatment Methods 7%
• Intravitreal 7%
• Visual Performance 7%
• Subretinal Space 7%
• Retinal Atrophy 7%
• PhD Studies 7%
• US Health Care 7%
• Care Plan 7%
• Monthly Dosing 7%
• Visual Prognosis 7%
• Ranibizumab Injection 7%
• Pro Re Nata 7%
• Legally Blind 7%
• Photoreceptor Cells 7%
• Visual Disability 7%
• Choroidea 7%
• Anti-VEGF Therapy 7%
• Ranibizumab Treatment 7%

Medicine and Dentistry

• Ranibizumab 100%
• Wet Macular Degeneration 100%
• Doctor of Philosophy 44%
• Visual Acuity 22%
• Vasculotropin Inhibitor 22%
• Disease 11%
• Epithelial Cell 11%
• Disease Activity 11%
• Serositis 11%
• Randomized Clinical Trial 11%
• Hazard Ratio 11%
• Injury 11%
• Optical Coherence Tomography 11%
• Vision 11%
• Vasculotropin 11%
• Fibrosis 11%
• Oxidative Stress 11%
• Photoreceptor Cell 11%
• Visual Pigment 11%

Pharmacology, Toxicology and Pharmaceutical Science

• Wet Macular Degeneration 100%
• Ranibizumab 100%
• Vasculotropin Inhibitor 22%
• Inflammation 11%
• Disease Activity 11%
• Disease 11%
• Injury 11%
• Randomized Clinical Trial 11%
• Vasculotropin 11%
• Visual Pigment 11%
• Fibrosis 11%